Mankind Pharma Limited

BSE: MANKIND543904ISIN INE634S01028

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹2,318.00+23.00 (+1.00%)

as of 18 Sep 2026

52W high: ₹2,670.00
52W low: ₹1,909.90
Off 52W high: -13.18%
1M return: -3.05%
3M return: -4.11%
6M return: +15.91%
1Y return: -12.14%
20D avg volume: 43,253
50 DMA: ₹2,426.92
200 DMA: ₹2,281.95

Key ratios Consolidated

Market cap: ₹95,744 Cr
Current price: ₹2,318.00
52W high / low: ₹2,670.00 / ₹1,909.90
Face value: ₹1.00
P/E: 46.30
P/B: —
EPS (TTM): ₹50.06
Book value / share: —
ROE: —
ROCE: 13.70%
Operating margin: —
Net margin: —
Debt / equity: 0.38
Net debt: ₹5,920 Cr
Interest cover: 4.63
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 64.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	4,031	3,443	3,567	3,697	3,570	3,079	3,230	3,077	2,893	2,441	2,607	2,708
	45.00	114.29	72.75	91.87	79.88	251.33	77.32	109.43	100.60	92.13	70.13	59.98
	3,310	2,878	3,028	3,167	3,113	2,818	2,813	2,339	2,330	1,964	2,119	2,131
	684.85	554.95	553.04	594.36	585.68	554.25	536.11	461.99	472.98	436.34	456.74	473.74
	547.28	498.36	411.67	412.97	404.97	411.12	387.30	424.28	432.99	342.29	352.79	363.33
	913.50	751.60	823.71	825.18	783.41	715.80	709.71	646.43	633.78	581.51	568.35	571.96
	109.98	141.75	157.20	169.68	170.65	190.54	220.93	7.10	10.91	9.38	9.19	8.62
	225.70	223.08	222.60	221.82	218.68	230.87	192.30	105.62	107.74	104.69	109.73	96.48
	962.63	803.08	846.07	888.48	886.58	805.00	755.27	705.15	765.35	531.20	604.51	628.63
	765.51	679.34	612.38	621.70	537.32	513.11	493.89	846.75	663.71	569.16	557.73	637.52
	0.00	-23.16	-106.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	765.51	656.18	505.79	621.70	537.32	513.11	493.89	846.75	663.71	569.16	557.73	637.52
	195.36	99.75	95.12	103.84	95.87	86.44	112.81	190.44	124.55	94.98	102.52	129.81
	574.09	559.42	413.88	520.18	444.62	424.65	384.52	658.88	543.07	476.59	459.81	511.18
	13.76	13.44	9.90	12.39	10.62	10.30	9.45	16.31	13.39	11.76	11.33	12.51
Key metrics
	1,101	1,021	885.59	1,013	926.65	934.52	907.12	959.47	782.36	683.23	676.65	742.62
	27.30%	29.70%	24.80%	27.40%	26.00%	30.30%	28.10%	31.20%	27.00%	28.00%	26.00%	27.40%
	14.20%	16.20%	11.60%	14.10%	12.50%	13.80%	11.90%	21.40%	18.80%	19.50%	17.60%	18.90%
	—	3.70%	—	3.60%	—	3.20%	—	—	—	—	—	—
	12.90%	11.80%	10.40%	20.20%	23.40%	26.10%	23.90%	13.60%	—	—	—	—
	29.10%	31.70%	7.60%	-21.10%	-18.10%	-10.90%	-16.40%	28.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	14,738	14,278	12,207	10,335	8,749
	323.91	358.79	536.79	280.86	128.57
	12,383	12,186	10,240	8,231	7,219
	2,387	2,288	2,016	1,854	1,814
	1,870	1,728	1,656	1,410	809.24
	3,314	3,184	2,692	2,275	1,918
	578.61	639.28	429.41	33.53	44.47
	893.20	886.18	621.22	398.25	325.92
	3,500	3,424	3,008	2,315	2,017
	2,679	2,451	2,504	2,384	1,659
	-129.75	-129.75	0.00	0.00	0.00
	2,549	2,321	2,504	2,384	1,659
	494.07	394.58	509.74	457.59	361.56
	2,068	1,938	2,011	1,942	1,310
	49.49	46.35	49.28	47.75	32.00
Key metrics
	4,021	3,846	3,555	2,816	2,029
	27.28%	26.90%	29.10%	27.20%	23.20%
	14.03%	13.60%	16.50%	18.80%	15.00%
	—	13.70%	13.30%	—	—
	—	17.00%	18.10%	18.10%	—
	—	-3.60%	3.60%	48.30%	—
	—	2,495	1,953	—	—
	—	1.61	1.20	—	—
	—	0.38	0.58	—	—
	—	5,920	8,104	—	—
	—	64.7	74.7	—	—
Balance sheet
	—	28,080	27,760	—	—
	—	7,140	7,175	—	—
	—	391.69	407.36	—	—
	—	1,730	1,538	—	—
	—	2,144	2,094	—	—
	—	805.25	802.82	—	—
	—	2,960	2,908	—	—
	—	1,341	1,133	—	—
	—	6,507	5,664	—	—
	—	6,312	8,511	—	—
	—	3,419	2,971	—	—
	—	2,893	5,540	—	—
	—	16,561	14,568	—	—
Cash flow
	—	3,121	2,413	—	—
	—	-196.42	-12,683	—	—
	—	-2,953	10,290	—	—
	—	625.96	460.79	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,964	2,582	2,633	2,609	2,541	2,127	2,397	2,530	2,403	2,153	2,359	2,453
	33.96	126.70	56.52	77.67	64.22	219.32	69.82	105.76	94.83	83.85	67.23	58.12
	2,241	1,898	2,100	2,162	2,112	1,917	1,942	1,865	1,921	1,692	1,849	1,900
	257.42	203.58	201.14	230.46	224.76	216.76	179.72	182.12	204.24	213.15	205.21	229.96
	560.44	419.66	452.66	432.84	414.47	384.25	445.60	484.31	503.96	477.13	500.36	538.46
	683.56	550.85	617.33	600.29	584.87	536.75	521.79	525.86	522.10	507.93	492.68	500.29
	94.95	125.28	138.37	147.20	146.70	162.25	199.47	1.92	6.26	4.03	4.26	4.31
	111.02	109.43	107.69	99.03	96.93	105.24	87.03	85.42	83.40	82.29	89.73	77.04
	624.67	538.87	575.16	604.54	613.78	555.44	474.45	548.48	622.47	474.47	533.07	551.52
	756.57	810.83	588.71	524.63	493.66	428.75	524.25	770.45	577.37	544.86	576.35	611.96
	0.00	-22.82	-83.42	0.00	0.00	0.00	—	—	—	—	—	—
	756.57	788.01	505.29	524.63	493.66	428.75	524.25	770.45	577.37	544.86	576.35	611.96
	198.08	74.40	55.82	65.73	80.90	46.29	107.87	168.01	93.12	90.69	89.28	139.08
	558.49	713.61	449.47	458.90	412.76	382.46	416.38	634.43	513.49	454.17	487.07	472.88
	13.53	17.29	10.89	11.12	10.00	18.54	10.35	15.04	12.09	11.34	12.16	11.80
Key metrics
	962.54	1,023	751.35	770.86	737.29	696.24	810.75	857.79	667.03	631.18	670.34	693.31
	32.50%	39.60%	28.50%	29.50%	29.00%	32.70%	33.80%	33.90%	27.80%	29.30%	28.40%	28.30%
	18.80%	27.60%	17.10%	17.60%	16.20%	18.00%	17.40%	25.10%	21.40%	21.10%	20.70%	19.30%
	—	4.80%	—	3.50%	—	3.00%	—	—	—	—	—	—
	16.60%	21.40%	9.90%	3.10%	5.70%	-1.20%	1.60%	3.10%	—	—	—	—
	35.30%	86.60%	7.90%	-27.70%	-19.60%	-15.80%	-14.50%	34.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	10,787	10,421	9,498	9,265	8,127
	294.85	326.10	493.21	266.64	162.78
	8,401	8,326	7,685	7,272	6,727
	892.60	860.52	800.43	861.74	711.05
	1,866	1,729	1,810	2,072	1,866
	2,452	2,367	2,132	1,982	1,701
	505.80	562.21	371.76	14.57	27.75
	427.17	428.57	378.01	317.61	269.58
	2,343	2,343	2,207	2,049	1,884
	2,681	2,421	2,306	2,260	1,563
	-106.24	-106.24	0.00	—	—
	2,574	2,315	2,306	2,260	1,563
	394.03	277.44	421.74	436.16	314.58
	2,180	2,038	1,945	1,823	1,248
	52.83	49.37	94.80	45.52	31.16
Key metrics
	3,507	3,306	3,056	2,592	1,860
	32.51%	31.70%	32.20%	28.00%	22.90%
	20.21%	19.60%	20.50%	19.70%	15.40%
	—	15.00%	13.60%	—	—
	—	9.70%	2.50%	14.00%	—
	—	4.70%	6.70%	46.10%	—
	—	2,415	2,024	—	—
	—	1.35	1.19	—	—
	—	0.34	0.50	—	—
	—	5,483	7,054	—	—
	—	55.0	54.6	—	—
Balance sheet
	—	24,625	23,828	—	—
	—	4,288	4,794	—	—
	—	87.66	200.29	—	—
	—	1,164	894.67	—	—
	—	1,088	1,091	—	—
	—	537.62	601.17	—	—
	—	1,939	1,941	—	—
	—	681.25	563.62	—	—
	—	5,473	4,092	—	—
	—	5,571	7,254	—	—
	—	3,042	2,308	—	—
	—	2,529	4,946	—	—
	—	16,397	14,640	—	—
Cash flow
	—	2,752	2,322	—	—
	—	-387.96	-12,115	—	—
	—	-2,477	9,783	—	—
	—	337.16	298.43	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +8.64%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: +17.74%
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): +12.44%
Profit YoY (TTM): +18.12%

Consolidated

Sales CAGR 3Y: +17.73%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: +13.96%
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): +13.75%
Profit YoY (TTM): +8.10%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 72.61%

Holder	Type	Holding	Previous	Change
Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee)	Promoter	20.18%	—	—
Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee)	Promoter	19.35%	—	—
Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee)	Promoter	14.95%	—	—
SHEETAL ARORA	Promoter	4.67%	—	—
PUJA JUNEJA	Promoter Group	2.79%	—	—
NPS TRUST - A/C SBI PENSION FUND SCHEME - CORPORAT	Public	2.77%	—	—
POONAM JUNEJA	Promoter Group	2.56%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF	Public	2.07%	—	—
ARJUN JUNEJA	Promoter Group	1.97%	—	—
RAMESH JUNEJA	Promoter	1.66%	—	—
RAJEEV JUNEJA	Promoter	1.57%	—	—
SBI ARBITRAGE OPPORTUNITIES FUND	Public	1.56%	—	—
GOVERNMENT PENSION FUND GLOBAL	Public	1.29%	—	—
EKLAVYA JUNEJA	Promoter Group	0.94%	—	—
CHANAKYA JUNEJA	Promoter Group	0.94%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report17 Sep 2026 · AGM/EGM / Postal Ballot
Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report17 Sep 2026 · AGM/EGM / Postal Ballot
Please find attached intimation regarding ESG Rating15 Sep 2026 · Company Update / General
Please find attached intimation of participation in the Investor Conferences11 Sep 2026 · Company Update / Analyst / Investor Meet
Please find attached update on voluntary liquidation of Bharat Serums and Vaccines Limited, a wholly owned subsidiary company.7 Sep 2026 · Company Update / General
Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP Plan1 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Please find attached final update on sale of stake of Broadway Hospitality Services Private Limited, a wholly owned subsidiary company.31 Aug 2026 · Company Update / General
Please find attached intimation regarding completion of term of Independent Director30 Aug 2026 · Company Update / Change in Management
Please find attached outcome of the Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limited, a wholly ....26 Aug 2026 · Company Update / Restructuring
Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly ....26 Aug 2026 · Others / Outcome without intimation
Please find attached intimation regarding ESG Rating22 Aug 2026 · Company Update / General
Please find attached press release dated August 20, 2026.20 Aug 2026 · Company Update / Press Release / Media Release
Please find attached Newspaper Advertisement of Notice of Postal Ballot19 Aug 2026 · Company Update / Newspaper Publication
Please find attched postal ballot notice18 Aug 2026 · AGM/EGM / Postal Ballot
Completion of realignment of Security Cover in respect of Non-Convertible Debentures.17 Aug 2026 · Company Update / General
Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands13 Aug 2026 · Company Update / Acquisition
Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director10 Aug 2026 · Company Update / Change in Management
Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director10 Aug 2026 · Company Update / Change in Management
Please find attached outcome of board meeting10 Aug 2026 · Others / Outcome without intimation
Please find attached intimation regarding participation in Investor Conferences10 Aug 2026 · Company Update / Analyst / Investor Meet
Please find attached Voting Results and Scrutinizer''s Report of 35th AGM6 Aug 2026 · AGM/EGM / AGM
Please find attached proceedings of the 35th AGM of the Company4 Aug 2026 · AGM/EGM / AGM
Please find attached transcript of the Investor Conference call for Q1FY27 held on July 30, 20264 Aug 2026 · Company Update / Earnings Call Transcript
Please find attached Newspaper Advertisement - Unaudited Financial Results of the company for the quarter ended on June 30, 202631 Jul 2026 · Company Update / Newspaper Publication
Investor Conference call for Q1FY27 - Audio Recording30 Jul 2026 · Company Update / Analyst / Investor Meet
Please find attached certificate under Regulation 54 of the SEBI (LODR) Regulations, 201530 Jul 2026 · Others / Reg. 54 - Asset Cover details
Please find attached press release on financial results of the Company for Q1FY2730 Jul 2026 · Company Update / Press Release / Media Release
Please find attached investor presentation for Q1FY2730 Jul 2026 · Company Update / Investor Presentation
Board of Directors of the Company in its meeting held today has inter-alia considered and approved the issuance of corproate guarantee in favour of Bharat Serums & Vaccines Limited, a WOS.30 Jul 2026 · Company Update / General
Please find attached un-audited financial results of the Company for the quarter ended on June 30, 202630 Jul 2026 · Result / Financial Results
Outcome of Board Meeting30 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation under Regulation 30 of the SEBI LODR27 Jul 2026 · Company Update / General
Please find attached intimation regarding investor conference call for Q1FY27.17 Jul 2026 · Company Update / Analyst / Investor Meet
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the unaudited standalone and ....16 Jul 2026 · Board Meeting / Board Meeting
Board of Directors of the Company has approved the divestment of 100 % stake held in Broadway Hospitality Services Private Limited, a wholly owned subsidiary company11 Jul 2026 · Company Update / Diversification / Disinvestment
Board of Directors of the Company in its meeting held today i.e., July 11, 2026 has approved the incorporation of a wholly owned subsidiary in Netherlands11 Jul 2026 · Company Update / Acquisition
Please find attached Outcome of Board Meeting held on July 11, 202611 Jul 2026 · Others / Outcome without intimation
Please find attached certificate under Regulation 74(5) of the SEBI DP Regulations, 2018 for the quarted ended on June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached newpaper advertisment regarding 35th Annual General Meeting of the Company10 Jul 2026 · Company Update / Newspaper Publication
Please find attached BRSR Report for the financial year 2025-269 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 1.0000	8 Aug 2025	8 Aug 2025	—

Board meetings

30 Jul 2026 Board Meeting - Financial Results